8-K filing — SUPERNUS PHARMACEUTICALS, INC. (SUPN)
Filed: 2026-10-29 AccNo: 0001356576-26-000050 Size: 461 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Newron Pharmaceuticals Completes Enrollment in Phase 3 ENIGMA-TRS 1 Study for Evenamide
Newron Pharmaceuticals has finished patient enrollment for its Phase 3 study of evenamide, a glutamate modulator for which Supernus Pharmaceuticals holds U.S. marketing rights.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Indivior Reports Q3 2026 Results and Confirms Imminent Merger with Supernus
Indivior Pharmaceuticals reported its third-quarter 2026 financial results and confirmed that its merger with Supernus Pharmaceuticals is expected to close on November 2, 2026.
Supernus Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript
Supernus Pharmaceuticals (NASDAQ:SUPN) held its second-quarter earnings conference call on Tuesday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time